RGCC Oncotrace serves as a valuable follow-up tool, accurately evaluating the therapeutic response of cancer treatment. It furnishes essential data necessary for comprehending and anticipating the prognosis of cancer.
RGCC Oncotrace serves as a valuable follow-up tool, accurately evaluating the therapeutic response of cancer treatment. It furnishes essential data necessary for comprehending and anticipating the prognosis of cancer.
RGCC Oncotrace guides disease progression and future prognosis. It also helps to identify a patient’s primary tumor in case of unknown primary origin. It precisely assesses the therapeutic response of cancer treatment and provides data that is pivotal for informed decision-making to enhance your overall health and well-being. The test assesses prognosis assessment and disease progression.
Oncotrace is a baseline test that provides data on the status of your cancer before starting the treatment. The test provides information on cancer progression and prognosis which is pivotal for informed decision making.
The test applies to all types of cancer and is not just limited to the following.
The first step towards personalized cancer care is scheduling an appointment with us.
Upon booking the appointment, you get a consultation with our RGCC experts to assess your cancer status.
We guide you through the process of selecting the most effective tests for your specific cancer.
We deliver precise results that guide treatment decisions and enhance outcomes.
“RGCC’s Oncotrace test is invaluable for monitoring cancer recurrence. Its precision enables early detection, facilitating prompt intervention and improved patient outcomes. A vital tool in post-treatment surveillance.”
Our RGCC accredited experts are here to help you with their expertise and guide you in your fight against cancer.
A simple non-invasive test to monitor cancer.
We suggest undergoing the RGCC Oncotrace test every three months during active cancer treatment to evaluate the efficacy of the ongoing treatment plan.
Every 3 months for 1 year after completing the treatment/surgery to monitor for early relapse/recurrence.
Once patients achieve full remission (when the CTC count is below 1 and all the CSC markers are negative), the test is recommended every six months.)
Our cutting edge diagnostics and personalised tests makes a meaningful difference in the fight against cancer.
Are you looking for precise insights into your therapeutic response? RGCC OncoTrace is an advanced tool to gain the clarity needed to make informed decisions and improve your treatment outcomes. Take charge of your cancer journey with confidence.